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ABSTRACT 
The functional diversity in factors identified in association with non-alcoholic fatty liver 
disease (NAFLD) necessitates the utilization of holistic approaches to investigate the 
‘network’ properties of NAFLD pathogenesis. We describe the generation of the first mouse-
specific multi-tissue metabolic model, the SteatoNet, to investigate NAFLD-related steatosis, 
by utilising an object-oriented modelling approach and incorporating numerous hepatic 
metabolic pathways, their interaction with peripheral tissues and hierarchical feedback 
regulation at the transcriptional and post-translational level. The unique validated model is 
based on steady-state analysis of ordinary differential equations that allows investigation of 
systemic behaviour in the absence of estimated kinetic parameters. Model analysis indicated 
the importance of the metabolic flux distribution parameter in controlling metabolite 
concentration and identified critical focal points in the network that may play a pivotal role in 
initiating NAFLD. Albeit requiring experimental validation, the candidate triggers identified 
by SteatoNet provide insight into the network properties of NAFLD and emphasize the 
promising scope and potential of SteatoNet as a primary investigative tool for hypotheses 
generation and exploring related metabolic diseases. 
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1. INTRODUCTION 
NAFLD, the hepatic manifestation of the metabolic syndrome, is the most common 
chronic liver disease among western populations, with a prevalence of 25-30% [1]. It 
encompasses a broad disease spectrum ranging from steatosis (hepatic accumulation of 
triglycerides), non-alcoholic steatohepatitis (NASH) that is additionally characterised by 
inflammation and progression into cirrhosis and hepatocellular carcinoma (HCC). 
Genome wide association studies (GWAS) studies have identified only a small number of 
genetic variants in association with NAFLD [2], which can be categorised into numerous 
different types of biological pathways such as inflammation, lipid and glucose 
metabolism etc. NAFLD has also been associated with aberrant xenobiotic metabolism, 
stemming from the close interactions and common regulators between lipid and drug 
disposition pathways [3]. Moreover, a majority of these SNPs are associated with a wide 
array of metabolic phenotypes highlighting the role played by genetic heterogeneity in 
multiple pathways in NAFLD pathogenesis, thus eliciting differences in phenotypes 
amongst NAFLD patients and determining the proportion of patients progressing into 
NASH and fibrotic stages [4]. Recent studies have also identified novel biological 
functions and pathways associated with NAFLD. Canonical pathway analysis has 
indicated an upregulation of the hepatic fibrosis pathway (COL1A1, IL10, IGFBP3) and a 
downregulation of the endoplasmic reticulum stress and protein ubiquitination pathways 
(HSPA5, USP25) along with highlighting cell development, morphology, cell movement, 
cell death and antigen presentation as the major biological functions associated with 
changes in gene expression in morbidly obese patients with NAFLD [5].  With 
perturbations in numerous pathways, NAFLD may be more accurately described as a 
‘network disease’ rather than arising due to the generalised 3-hit hypothesis, thus 
requiring global holistic approaches to understand the disease state [6-8].  
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Systems biology provides global and integrative approaches to investigate complex 
‘network diseases’ that are characterised by multiple causal mechanisms and disease 
outcomes. Firstly, with the advent of high-throughput data generation, it allows the 
correlation of vast amounts of data types. A combination of computational and systems 
biology provides a powerful tool to enhance the analytical abilities of experimental 
biology [9] and has also been utilised to identify candidate genes associated with NAFLD 
[10] and common disease-associated modules between NAFLD and alcoholic fatty liver 
disease (ALD) [11]. Secondly, it provides an opportunity to systematically model and 
simulate non-linear biological systems. Hence, rapid and inexpensive in silico simulations 
to test various hypotheses prior to experimentation can economise time and resource 
utility. Thirdly, network validation and analysis provides intuition for unidentified and 
uncharacterised regulations in known biological pathways that may not have been 
realised otherwise [12, 13]. 
Numerous hepatic pathway-specific models have been generated for the cholesterol 
synthesis pathway [14, 15], the interaction between glucose and lipid metabolism [16, 
17], hepatic mitochondrial functions [18] etc. that have identified key local behavioural 
mechanisms in these pathways and their regulation. The HepatoNet1 is a dynamic 
network focusing on molecular interactions within a single hepatocyte cell [19]. It 
includes 777 metabolites, 2539 reactions and 1466 transport reactions. This tissue-
specific genome-scale model of the hepatocyte, validated for several metabolic objectives 
based on the criterion for metabolic flux minimization [20], provides a comprehensive 
functional model of hepatocyte metabolism. Similarly, an extensive scientific venture 
‘The Virtual Liver Network’ aims to build a multi-scale organ model of the liver with 
spatial and temporal attributes [21]. While these hepatocyte and liver models have 
immense potential to investigate liver- specific functions, they may be less informative to 
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study the aetiology of complex systemic diseases such as NAFLD, which is characterised 
by deregulations in multiple tissues [22]. Hence, systemic modelling of the interaction of 
the liver with peripheral tissues, as described in the article, will provide greater insight 
into potential mechanisms of NAFLD pathogenesis.   
In this article we describe a mouse-specific multi-pathway and multi-tissue model, 
SteatoNet (Steatosis Network), based on ordinary differential equations (ODEs) to study 
the network properties of hepatic steatosis, the initial stage of NAFLD pathogenesis. The 
choice of mouse as the model organism, as opposed to the focus on human metabolism in 
the HepatoNet1 and Virtual Liver projects, provides a unique model to analyze pre-
clinical experimental data. Moreover, a majority of the analyses conducted in relation to 
NAFLD and the regulatory mechanisms of metabolic pathways have been implemented 
in mouse models due to their ease of manipulation, tractability and the availability of 
study samples. We implement a steady-state based analysis of ODEs that does not require 
kinetic parameters and can uniquely identify a solution by defining the reversibility of 
reactions, the distribution of fluxes at pathway branch-points and the influx into the 
network at initial steady-state. It should however be noted here that parameters estimated 
from this type of analysis are semi-quantitative and provide insight into global system 
behaviour rather than accurate predictive values. A key feature of biological systems is 
the robustness displayed by pathways and the cumulative effect of regulatory mechanisms 
are central to maintaining this property [23]. Hence, regulatory mechanisms at both the 
transcriptional and post-translational level that have been associated with mouse 
metabolic pathways and proved experimentally to-date have been incorporated in the 
SteatoNet. Moreover, we mathematically show the dependence of metabolite 
concentration on the initial steady-state metabolic flux distribution and further conduct a 
sensitivity analysis on SteatoNet to identify flux distribution branch-points in various 
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pathways that directly influence hepatic triglyceride concentration. Results from this 
analysis support the hypothesis of network perturbations in NAFLD pathogenesis and the 
importance of wide-scale modelling to understand complex biological behaviours and 
diseases. 
 
2. METHODS 
 
2.1 Dynamic modelling and steady state analysis 
A systems biology library of object classes based on ordinary differential equations 
(ODEs) corresponding to biological pathway entities was generated for network 
construction, which includes the basic model generation objects such as enzyme, 
metabolite, non-enzymatic protein, mRNA, gene, flux sources and positive and negative 
regulatory objects for gene expression and protein regulation. The modelling method and 
model analysis in steady-state utilised has been detailed previously [15]. The reaction 
dynamics (Figure 1) are described by four reactions in an extension to the Michaelis-
Menten model of enzymatic kinetics: 
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where S,E,C and P denote the concentrations of the substrate, enzyme, substrate-enzyme 
complex and product respectively,  denotes the rate constant of complex formation,  
denotes the rate constant of product formation,  denotes the rate constant of complex 
dissociation into the enzyme and substrate and  denotes the rate constant of the 
product reversibility to complex.  corresponds to the substrate influx into the reaction, 
corresponds to the product efflux of the reaction,  corresponds to the influx of 
enzyme into the reaction,  corresponds to the degradation of enzyme and f denotes the 
proportion of the total substrate influx into alternative pathways.  
The concentrations of S, E, C and P at steady-state are represented by , ,  and 
. These variables can be converted into dimensionless quantities by normalising them 
with their steady-state counterparts. Thus, 
 
 
 
In an extension to the method described in Belič et al [15], an additional steady-state ratio 
is described to define the relative concentration of free and bound enzyme: 
 
 
 
Thus, the normalised value of the complex is determined in terms of the free enzyme 
concentration at steady-state rather than the steady-state complex concentration. Hence, 
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Similar to derivations in Belič et al, the steady state normalised values  and  are 
equal to 1 and according to the relation described above,  . The rate constants are 
now described with the incorporation of   : 
 
 
 
 
 
 
Thus, all the model parameters can be uniquely calculated with the knowledge of the 
reversibility of the reaction r, the distribution of the influx f into alternative pathways, the 
total influx  and the ratio between the bound and free enzyme, w. To derive the 
relations of the parameters at the new steady-state, , ,  and , at which 
the system settles in the event of a disturbance, we substitute these parameters into the 
steady-state form of equations 1 and 2: 
 
 
 
 
Solving for new steady-state concentration of the enzyme, substrate and product: 
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Equations 14-16 illustrates that apart from the classical interdependence between 
substrate, product and enzyme concentration, as stated by the Michaelis-Menten relations, 
these concentrations are also dependent on the distribution of the influx into alternative 
pathway branches and the reversibility of the reaction, however, they are not directly 
dependent on the absolute value of the total metabolic flux. The reversibility of a 
reaction, r, is an inherent property of the enzyme and the equilibrium constant between 
the species involved in the reaction. Although, the squared form of r diminishes its 
influence on the concentration of the substrate, enzyme or product, it accounts for the 
thermodynamic constraints related to Gibb’s free energy in the reactions. The flux 
distribution, , in metabolic pathways in the event of a disturbance, on the other hand, is 
a parameter that adapts itself depending on substrate influx into the network, the demand 
of a product in downstream pathways, alterations in enzyme concentration and also 
depends on the initial flux distribution in the network, .  
 
2.2 Gene expression regulation 
In addition to the biological entities involved directly in metabolic reactions, feedback 
regulation was also incorporated into SteatoNet. mRNA transcription was modelled as a 
sigmoid function with separate objects classes specified for positive and negative 
expression regulation. Negative expression control is described by the following 
equation: 
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where QmRNA represents relative concentration of mRNA, Qmax is the maximum relative 
mRNA expression,  is the transcription flux,  represents the concentration of the 
controlling molecule and kd depicts the rate of mRNA degradation. Similarly, positive 
expression control is described by the following equation: 
 
 
 
where  represents the maximum concentration of the regulator that results in the 
maximum fold-change in mRNA expression ( ). The generation of protein is 
described as a linear relation between the relative concentration of mRNA and 
protein/enzyme quantity ( ): 
 
 
 
where  represents the rate constant of mRNA translation and  is the rate constant of 
protein degradation. The quantity of the controlling molecule (QC) is usually controlled 
by activation or deactivation of the molecule by some metabolite quantity (QM), which is 
described in a linear manner as well. The rate equation for protein activation is: 
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Whereas, the rate equation for protein inactivation is: 
 
 
 
where  and  represent the pool of inactive and active protein, respectively,  and 
 are factors describing the activation or inhibition of the protein and the  term in 
equations 20 and 21 accounts for the rate of protein degradation. Although the linear 
representation of translation and post-translational protein regulation provides a 
simplified depiction of the actual process; it sufficiently represents regulatory mechanism 
in biology and is several fold more informative compared to models without any feedback 
control.  
 
2.3 SteatoNet construction 
An object-oriented modelling and simulation programme, Dymola (Version 7.4, Dassault 
Systems, Lund, Sweden), which is based on the open Modelica language, was utilized to 
generate SteatoNet, a dynamic non-linear model focussing on mouse-specific lipid and 
glucose metabolism, by compilation of reaction objects, governed by the system of 
equations as described in [15] and in the previous sections. Thus, a closed network of 
multi-reaction pathways is formed by linking reactions to each other and to regulatory 
objects with connectors (Figure 2). The pathways included in SteatoNet are based on 
mouse-specific biological pathway evidence obtained from Kyoto Encyclopaedia of 
Genes and Genomes (KEGG, http://www.genome.jp/kegg/) and the Reactome 
(www.reactome.org) databases for glucose, lipid and amino acid metabolism within the 
liver, adipose tissue, peripheral tissue, pancreas and macrophages. The regulation of the 
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network at the transcriptional and post-translational level has been incorporated based on 
manual literature (n>500) searches.   
 
2.4 Assignment Of Metabolic Flux Distributions 
Considering the complex interconnected topology of biological systems, the presence of 
pathway branching at several points in the network is a common occurrence. The 
distribution of the metabolic flux, f, in each of the pathway branches is an independent 
parameter that must be specified into the model by additional equations that set the initial 
ratio of flux distribution from the parent pathway into each branch. Vo et al [24] 
generated a comprehensive flux network based on isotopomer tracer analysis in HepG2 
cells, a hepatic carcinoma cell line. The estimated reaction fluxes from this study were 
utilised to approximate the value of f at various branch-points within SteatoNet. The 
choice of utilising flux analysis data from a human cell line compared to a mouse cell line 
was governed by the lack of comprehensive isotopomer analysis on mouse 
hepatocyte/liver in a normal physiological state and including a broad range of metabolic 
pathways. Moreover, based on flux variability analysis, Sigurdsson et al [25] indicated 
the highest degree of flux similarity between mouse and human metabolism compared to 
other mammals. Thus, it can be argued that the utilization of flux estimates from HepG2 
cells may not significantly affect the species-specificity of the SteatoNet. Furthermore, 
the flux estimates from the Vo et al study were utilised for only approximating f at 
branch-points within SteatoNet in order to gauge a physiological value for parameter 
assignment, while taking into consideration that in vitro isotopomer studies are subject to 
large variances as a result of differing cell culture conditions, sampling, pre-analytical 
processing etc [26] and do not realistically depict organism-level flux distributions 
resulting from inter-tissue interactions [27]. The flux distribution proportion was 
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calculated by summing the total flux at the branch-point and determining the proportion 
entering each branch as a fraction of the total flux. The choice of tracers in the Vo et al 
study and the utilization of cell lines prevented the identification of flux distributions in 
the lipid metabolism pathway and metabolite transport and distributions amongst 
different tissue types. Thus, at these branch-points with uncertainty in the flux 
distribution parameters, f was assigned an arbitrary value that resulted in stable model 
simulations. For several ‘stiff’ branch-points, the value of f was not completely arbitrary 
as these focal points can tolerate only a low range of flux distributions. Supplementary 
table 1 provides a complete list of the flux distribution proportions assigned to pathway 
branch-points in SteatoNet. It must be highlighted here that due to the semi-quantitative 
nature of the SteatoNet, the normalization of model parameters and the modelling goal 
which aims at identifying candidate mechanisms involved in NAFLD pathogenesis; the 
assignment of values to the parameter f is critical is terms of model identification rather 
than quantitative reproduction of hepatic function. Hence, the assignment of arbitrary flux 
distribution values is feasible in this case, provided that the model generates stable 
simulations and can simulate biological phenomena for model validation purposes. 
2.5 Sensitivity analysis 
The dependence of parameters on the model behaviour can be determined by sensitivity 
analysis, which is defined as the change in the model property versus the change in a 
parameter value [28].  Metabolic control analysis (MCA) is an extension of local 
sensitivity analysis to determine the extent of change in metabolic flux or other systemic 
properties achieved by a fractional change in enzyme activity [29]. MCA is quantified by 
control coefficients, which is termed as the flux control coefficient if the change in flux is 
considered as the model variable or as the concentration control coefficient if the change 
in concentration is considered as the model variable under study [28]. Relevant to this 
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article, we can define the concentration control coefficient as the partial derivative of the 
change in triglyceride metabolite concentration with respect to small changes in the 
distribution of fluxes,  , at various pathway branch-points. Thus, the 
sensitivity/concentration control coefficient is calculated by: 
 
 
 
where  is the concentration control coefficient of parameter  with respect to hepatic 
triglyceride concentration  and  and are the corresponding triglyceride 
concentrations at flux distribution values of   and . The second term in the equation, 
the ratio between the initial flux distribution and triglyceride concentration, is 
incorporated to obtain relative sensitivity coefficients that are dimensionless. Graphically, 
the control coefficient is the tangent to the curve describing the relation between the 
metabolite concentration and model parameter variation and hence, is dependent on the 
steady state under investigation. To determine the sensitivity of hepatic triglyceride 
concentration to the metabolic flux distribution, the glucose and triglyceride influx into 
the network was increased by 10-fold to simulate a disturbance in the system on high-
glucose and high-fat diet and the distribution parameter for each branch point in the 
pathway model was varied by an interval of 10%. The corresponding changes in hepatic 
triglyceride synthesis were recorded and concentration control coefficients were 
calculated. In an extension of the flux distribution sensitivity analysis and equation 22, 
the effect of flux alterations in branch-points with high  on the concentration of 
regulatory factors in SteatoNet was determined, under similar conditions as described 
above, by the following equation: 
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where  is the concentration control coefficient of parameter  with respect to the 
concentration of the regulator , and  and are the corresponding regulator 
concentrations at flux distribution values of   and . 
 
3. RESULTS AND DISCUSSION 
A dynamic, semi-quantitative, multi-tissue metabolic model, the SteatoNet, focussing on 
the metabolic function of hepatocytes and their interaction with extra-hepatic 
compartments has been generated by utilising an in-house object-oriented systems 
biology library based on ODEs. An advantage of object-oriented modelling is the 
reusability of general equations and model object classes, thus avoiding tedious, error-
prone manual coding methodologies for building complex systems. In addition, it also 
provides a user-friendly graphical interface that reduces the modelling effort. The 
pathways included in SteatoNet are glycolysis, gluconeogenesis, citric acid cycle, pentose 
phosphate pathway, de novo lipogenesis, β-oxidation, lipolysis, cholesterol metabolism, 
amino acid metabolism and ketone body synthesis. Moreover, compared to the numerous 
existing hepatic metabolism models, a unique highlight of the SteatoNet is the portrayal 
of the exchange of metabolites and regulatory molecules between the liver, adipose 
tissue, peripheral tissues, pancreas and macrophages, via the blood. The enzyme levels in 
these pathways are governed by gene expression objects, which are in turn regulated by 
transcription factors such as peroxisome proliferator activated receptor alpha (PPARα), 
PPARγ, sterol-regulatory element binding protein 1c (SREBP-1c), SREBP2, 
carbohydrate-response element-binding protein (ChREBP), liver X receptor (LXR), 
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farnesoid X receptor (FXR), glucocorticoid receptor and PPARγ coactivators 1 alpha 
(PGC1A). Furthermore, the regulatory actions of the hormones insulin and glucagon, the 
adipokines leptin and adiponectin and the cytokine tumour necrosis factor alpha (TNFα) 
have been incorporated into the network. A total of 194 reactions involving 159 
metabolites, 224 enzymes and 31 non-enzymatic regulatory proteins are represented in 
SteatoNet. This multi-compartmental and multi-pathway model including feedback 
regulation at the transcriptional and translational level provides a well-approximated 
portrayal of the biological system under consideration. 
 
3.1 Model Validation 
To determine if SteatoNet correctly depicts biological phenomena, model simulations 
were compared to experimental observations obtained from the literature. The model was 
translated by utilising the Microsoft visual studio 10.0 C compiler and the simulations 
were generated by utilising the default multi-step dassl solver in Dymola with a tolerance 
set to 1e-009. Taking into consideration the assumptions of the model, the initial 
normalised steady state concentration of all metabolites and enzymes has a value of 1.0 
and on model perturbation the model variables are estimated based on the input values of 
r, f, w and . The simulations thus generated depict relative semi-quantitative changes in 
the network components in response to triggers causing a shift from the initial steady 
state of the model. Metabolic changes in response to fasting, the absence of stearoyl-CoA 
desaturase (SCD), a crucial lipogenic enzyme, and overexpression of adiponectin, an 
insulin-sensitising anti-inflammatory cytokine released by the adipose tissue have been 
well studied and were utilised to validate the model. Inconsistencies between biological 
observations and model simulations mainly occur due to the errors or missing objects and 
regulatory connections in the model. In the presence of inconsistencies, a series of 
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simulations was implemented to identify the network objects that display erroneous 
behaviour and further in-depth literature searches were performed in the context of these 
objects to identify regulations that have been established experimentally but were absent 
in the network. 
3.1.1 Fasting 
The fasted or starved state is characterised by low glucose and insulin levels and 
increased glucagon in the blood. Glucagon activates glycogen phosphorylase for 
the breakdown of stored glycogen into glucose and inhibits glycogen synthase. It 
upregulates gluconeogenesis by increasing the expression of phosphoenolpyruvate 
carboxykinase (PEPCK) and downregulates fatty acid synthesis by deactivating 
acetyl CoA carboxylase 1 (ACC1). Glucagon also inhibits glycolysis by 
downregulating an activator of phosphofructokinase-1 (PFK1), a key rate-limiting 
enzyme in glucose metabolism [30]. Fasting has also been shown to induce 
peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor that 
regulates mitochondrial and peroxisomal fatty acid oxidation [31]. PPARα-null 
mice display hypoglycaemia and an upregulation of serum free fatty acids. 
Additionally, fatty acid release from adipose tissue stores and oxidation is also 
regulated by fatty acid-induced adipose factor (FIAF), which is upregulated 
during fasting [32].  
To simulate fasting conditions, the influx of glucose substrate into the network 
was reduced by 10-fold compared to the initial steady state. Figure 3 shows 
simulations of the levels of insulin, glucagon, blood glucose, serum fatty acids, 
PEPCK, ACC1, fatty acid synthase (FAS), sterol response element-binding 
protein- 1c (SREBP1c) and the β-oxidation enzyme, carnitine acyl transferase-1 
(CPT-1) in response to the reduced glucose influx into the network. As observed 
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from the simulations in Figure 3, the resulting downregulation of serum insulin, 
serum glucose, glycogen stores, lipogenic enzymes (ACC1 and FAS) and their 
regulator SREBP1c and increased levels of serum glucagon, serum fatty acids, the 
gluconeogenic enzyme, PEPCK, and the β-oxidation enzyme, CPT-1, corresponds 
accurately to the expected changes in the fasted state.  
 
3.1.2 Stearoyl CoA knockout 
Stearoyl CoA desaturase (SCD) is a rate-limiting delta-9 desaturase enzyme 
involved in lipogenesis [33, 34]. It catalyses the desaturation reaction to convert 
saturated fatty acids into monounsaturated fatty acids, in particular oleate (18:1) 
and palmitoleate (16:1). Monounsaturated acids serve as the key building blocks 
of triglycerides, cholesterol esters and membrane phospholipids [35]. The SCD-1 
isoform is predominantly expressed in the liver and its expression is tightly 
regulated by transcription factors such as SREBP-1c [36], liver X receptor (LXR) 
[37] and PPARα [38], leptin [39] and estrogen [40]. SCD -/- mice fed with a high 
fat diet display a protection against diet-induced obesity and increased insulin 
sensitivity compared to wild-type mice due to increased fatty acid oxidation and a 
downregulation in lipogenesis [41]. Although a lipogenic (high-carbohydrate) diet 
increases the expression of genes involved in de novo lipogenesis, SCD -/- mice 
fed with a lipogenic diet still display low levels of triglycerides indicating the 
crucial role of SCD-1 in regulating triglyceride synthesis [42]. In addition, SCD-1 
activity is increased in NAFLD patients [43].  
To simulate the SCD knockout condition, the rate of SCD enzyme degradation 
was increased by 1000-fold, resulting in SCD enzyme concentration approaching 
0. The lipogenic diet was simulated by increasing the glucose influx by 10-fold 
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and the high-fat diet were simulated by increasing the triglyceride and cholesterol 
influx by 5-fold and 4-fold, respectively, and decreasing the glucose influx by 2.5-
fold. Figure 4 illustrates the effects of SCD absence on a lipogenic diet until time 
105 and high-fat diet between time 105 and 2x105. Simulations of the response of 
triglycerides, fatty acid oxidation and lipogenesis enzymes to SCD knockout 
indicate a decrease in hepatic triglyceride accumulation and increase in the level 
of CPT-1 on both diets. While the lipogenic enzyme glycerol-3-phosphate 
acyltransferase (GPAT) and its transcriptional regulator SREBP-1c were 
upregulated under lipogenic diet conditions, their concentrations decreased on a 
high-fat diet, in concordance with experimental observations in rodent models. 
 
3.1.3 Adiponectin overexpression 
Adiponectin is an adipose-secreted cytokine that has a negative correlation with 
insulin resistance, plasma triglycerides and low-density lipoprotein (LDL) – 
cholesterol, hepatic fat content and progression to NASH in NAFLD patients [44-
46]. It is known to affect glucose metabolism by repressing hepatic glucose 
production via the activation of adenosine monophosphate-activated protein 
kinase (AMPK) α-2 in hepatocytes [47]. The beneficial impact of adiponectin on 
metabolism is enforced by the ceramidase activity of its receptors, AdipoR1 and 
AdipoR2, to lower hepatic levels of ceramides, which are bioactive lipids 
implicated in insulin resistance [48]. Shetty et al [49] observed a 30% decrease in 
plasma fatty acids, an upregulation in ketone bodies and fatty acid oxidation in the 
adipose tissue and decreased expression of lipogenic genes on fasting in 
adiponectin-overexpressing transgenic mice. Whilst adiponectin has insulin-
sensitizing, anti-inflammatory and antilipogenic effects, the adipokine, tumour 
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necrosis factor alpha (TNF-α) is thought to be a suppressor of adiponectin, with 
adiponectin-null mice displaying high levels of TNF-α mRNA and protein levels 
and diet-induced insulin resistance, thus explaining the phenomenon of increased 
TNF-α levels in obese populations [50]. The proinflammatory and insulin-
desensitising effects of TNF-α, potentially via the activation of other cytokines 
such as inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) and 
nuclear factor kappa-B (NF-κB), is well documented [51]. Thus, a balance 
between adiponectin and TNF-α level may determine the susceptibility to NAFLD 
progression.  
To simulate the overexpression of adiponectin under fasting conditions, the rate of 
adiponectin degradation was decreased by 10-fold, resulting in increased levels of 
adiponectin and the glucose substrate influx into the network was reduced by 10-
fold. The levels of hepatic triglycerides, serum fatty acids, hepatic lipogenic 
genes, ketone bodies, adipose β-oxidation enzymes, TNF-α and ceramides were 
simulated in response to the overexpression of adiponectin (Figure 5). In 
concordance with experimental observations, increased adiponectin concentration 
results in downregulation of serum fatty acids, hepatic triglycerides, TNF-α, 
ceramides, lipogenesis mediators SREBP1c, GPAT and SCD1 and increased 
expression of adipose CPT-1 indicating an upregulation of β-oxidation in 
adipocytes. The model simulation however, did not indicate any changes in serum 
ketone body concentration on adiponectin overexpression.   
 
3.2 Flux distribution sensitivity analysis 
Metabolic flux through a pathway is a crucial parameter and its value may depend 
upon flux entering the network, enzyme activity or concentration and genetic 
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variations. The interconnected nature of metabolic networks results in the frequent 
occurrence of branch-points in pathways resulting in the distribution of fluxes into 
daughter branches. Since NAFLD has been previously reported to result from 
increased fatty acid flux from adipose tissue [22], it may be hypothesised that 
additional flux distributions may be disrupted in the disease. Thus, we aimed to 
conduct a sensitivity analysis to identify flux branch points in the SteatoNet that 
display a significant influence on hepatic triglyceride accumulation.  
The concentration control coefficients with respect to hepatic triglyceride, , of 
each branch-point was determined over a broad range of flux distribution percentages 
on system perturbation. According to their , the branch-points were classified as 
focal points with ‘high sensitivity’ ( >1), ‘moderate sensitivity’ 
( ), ‘low sensitivity’ ( <0.1) or ‘null sensitivity’ (  = 0). 
Amongst the high sensitivity branch-points, those that displayed dynamic changes in 
their  over the varying flux range were further sub-classified as ‘high dynamic 
sensitivity’ branch-points (Figure 6). In addition, several branch-points displayed low 
tolerance to flux changes and were sub-classified as ‘high/moderate/low sensitivity + 
low tolerance’ branch-points (Tables 1-3).  The sensitivity of transcription and 
regulatory factors to alterations in branch-point flux distributions was also 
determined. Pathway branch-points with high dynamic or high dynamic + low 
tolerance  and regulatory factors that are sensitive to alterations in flux 
distributions at these branch-points are illustrated in Figure 7. 
 
3.2.1 Branch-points with high dynamic  
Sensitivity analysis in SteatoNet identified the prevalence of high dynamic 
sensitivity branch-points in the glucose metabolism and transport, lipid transport 
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and ketone body synthesis and transport pathways. While the tolerance to varying 
flux distributions at these branch-points is high, their  displayed significant 
variations over the broad flux distribution range. As observed from Figure 7, a 
majority of the high dynamic sensitivity branch-points (in bold) occur in the inter-
tissue transport pathways, highlighting the crucial role played by metabolite 
transport and redistribution amongst the different tissue types.  
 
Lipid Metabolism 
Figure 7 illustrates an enrichment of the lipid metabolic pathways amongst the 
branch-points with high dynamic . These include activation and desaturation 
of adipose fatty acids and the reactions that contribute to the adipose fatty acid 
pool such as fatty acid lipolysis in the adipocyte and transport between the blood, 
adipocyte and peripheral tissues (Figure 6a and b, Figure 7); the contribution of 
the diet via chylomicrons and VLDL breakdown to serum fatty acids (Figure 6c, 
Figure 7); and the transport of serum cholesterol to the liver (reverse cholesterol 
transport via HDL), adipose tissue and peripheral tissues (Figure 6d and e, Figure 
7). Previous studies have indicated an increased flux of adipose-derived non-
esterified fatty acids that contributes to hepatic triglyceride concentration in 
NAFLD patients [22]. In correspondence with this observation, the high negative 
of the desaturation and activation of adipose fatty acids and the transport 
reactions contributing to the adipose fatty acid pool highlighted by the SteatoNet 
(Figure 6a and b) indicates the negative correlation between adipose-specific 
lipogenesis and hepatic triglyceride concentration.  
The inter-tissue distribution of cholesterol and source of accumulated hepatic 
cholesterol in NAFLD patients or animal models has not been clearly established. 
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Cholesterol accumulation, along with increased expression of low density 
lipoprotein receptor (LDLR) or genes in the cholesterol synthesis pathway has 
been observed in an obese insulin-resistant rodent model of NAFLD and NAFLD 
patients respectively [52, 53], which contributes to hepatic lipotoxicity and 
progression to NASH [52, 54]. A study in obese children indicated an increased 
risk of NAFLD development in cases with increased total serum cholesterol and 
LDL [55]. In accordance with these clinical observations, the sensitivity analysis 
indicated the role of the reverse cholesterol transport pathway and deregulated 
cholesterol distribution to the adipose and other peripheral tissues in hepatic 
steatosis (Figure 6d and e, Figure 7).  The highly dynamic positive  of LDL 
distribution to the adipose and peripheral tissue implies that low to moderate LDL 
fluxes towards non-hepatic compartments does not affect hepatic triglyceride 
concentration significantly. However, at higher LDL flux distributions to the 
adipose and peripheral tissues, the positive correlation to hepatic triglyceride 
increases exponentially. This observation can be explained by studies that have 
indicated the role of LDL-cholesterol transport to the liver in ensuring 
triglyceride-rich VLDL secretion [56]. Thus, there appears to be a fine balance in 
the concentration and source of cholesterol in determining its role in sustaining 
VLDL secretion to prevent steatosis or causing lipotoxicity. It may also be 
speculated that these paradoxical roles of cholesterol establish the stage of 
NAFLD (steatosis or NASH). Additionally, tracer studies with labelled substrates 
may prove useful to determine the contribution of de novo cholesterol synthesis 
and lipoprotein-derived cholesterol in establishing the fate of cholesterol in the 
NAFLD disease state. These observations thus lay emphasis on the importance of 
cholesterol in NAFLD pathogenesis even at early stages of the disease, in addition 
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to the currently accepted notion of cholesterol-induced lipotoxicity in triggering 
NASH. 
 
Glucose metabolism 
The exchange of glucose between the serum and liver, the initial steps of the 
glycolysis pathway, the transport of glucose to the adipose tissue and the 
contribution of dietary glucose to serum glucose level display a high dynamic 
influence on hepatic triglyceride concentration (Figure 6f-h, Figure 7). High 
carbohydrate consumption, especially fructose, has been linked to triggering 
NAFLD [57, 58] as sugars provide precursors for fatty acid, triglyceride and 
cholesterol synthesis. Additionally, glucose metabolism has been implicated in 
NAFLD as type II diabetes and insulin resistance are predominant characteristics 
in NAFLD patients and are associated with the severity of the disease [59, 60]. 
Insulin plays a crucial role in glucose uptake and gluconeogenesis inhibition and 
additionally regulates de novo lipogenesis by activating SREBP1-c and thus 
upregulating ACC1 and FAS [61, 62]. The lipogenic role of insulin may thus be 
causal of the moderately positive  of the hepatic release of glucose into the 
blood (Figure 6h, Figure 7), which triggers insulin secretion. The high dynamic 
positive  of glucose transport to adipose tissue (Figure 6d, Figure 7) indicates 
a positive correlation between hepatic triglyceride concentration and increased 
glucose flux to adipose tissue, which potentially stems from the resulting 
upregulation of precursors available for de novo lipogenesis in adipocytes and 
hence, larger lipid depots that increase the fatty acid flux towards the liver on 
lipolysis. Hence, the transport of glucose and increased dietary intake may directly 
provide increased substrate flux for de novo triglyceride synthesis or/and may 
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indirectly be involved in regulating hepatic triglyceride concentration via the 
action of insulin.  
The high dynamic negative  of the generation of fructose-6-phosphate from 
glucose-6-phosphate (Figure 7 and Figure 6f), the first step of glycolysis, indicates 
a general negative correlation between hepatic triglyceride concentration and 
glycolysis. The negative correlation can be explained by the decreased activation 
of lipogenic factors ChREBP and SREBP1c by glucose [63] and insulin [64], 
respectively, as a result of glucose catabolism. The dynamic profile of the 
indicates that at low flux proportions towards glycolysis, the decrease in 
hepatic triglyceride concentration is much more significant than at higher flux 
values due to the low availability of precursors for de novo lipogenesis as well as 
decreased glycerol-3-phosphate production, which is required for triglyceride 
synthesis. Thus, the SteatoNet indicates the beneficial effects of glucose oxidation 
on hepatic steatosis however; the extent of the benefit is dependent on the 
glycolytic flux directed towards lipogenesis. At low glycolytic flux, the role of 
glucose is predominantly in ATP-generating oxidation via the TCA cycle rather 
than de novo lipogenesis.  
 
Ketone body metabolism 
Sensitivity analysis further highlighted the high negative  of the synthesis and 
transport of ketone bodies, acetoacetate and β-hydroxybutyrate (BHB) (Figure 6i-
k, Figure 7) indicating a negative correlation between hepatic triglyceride 
concentration and ketogenesis. In concordance with this observation, a genetic 
screen in a zebrafish model of hepatic steatosis highlighted the role of solute 
carrier family 16a, member 6 a (Slc16a6a), a transporter of BHB in hepatic 
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accumulation of triglycerides [65]. A mutation in this transporter diverted BHB as 
a substrate for de novo lipogenesis. Serum levels of ketone bodies also indicate 
the extent of mitochondrial β-oxidation in the liver [66]. Thus, the synthesis and 
extra-hepatic transport of ketone bodies is an indicator of hepatic triglyceride 
concentrations, as confirmed by the sensitivity analysis in our model. However, 
the less prominent downregulation of hepatic triglyceride concentration at 
increased fluxes in ketone body synthesis and transport pathway may occur due to 
a decrease in mitochondrial acetyl CoA flux towards the citric acid cycle for 
energy release, in addition to the increased availability of precursors for 
triglyceride synthesis in adipose tissue that may eventually be transported to the 
liver. 
 
3.2.2 Stiff branch-points with high  
Several pathway branch-points displayed high, medium or low  but only over 
a limited flux distribution range. Beyond this range, the perturbed model incurred 
instability in the absence of attainment of a new steady state. Branch-points with 
high values of   and low flux range tolerance (Table 1, Figure 7, not in bold) 
are mainly present in the triglyceride metabolism pathway, which include the 
formation of hepatic lysophosphatidic acid (LPA), the first step in triglyceride 
synthesis; the breakdown of adipose triglycerides into diacylglycerol (DAG); the 
storage of triglycerides in adipose lipid droplets and the synthesis of adipose 
dihydroxyacetone phosphate (DHAP), which is a precursor for glycerol-3-
phosphate involved in de novo lipogenesis (Figure 7). These focal points in the 
network may play a key initiating role in NAFLD by causing instability under 
conditions of even slight alterations in flux distribution. This observation is 
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supported by several studies implicating the role of adipose triglyceride 
storage/hydrolysis by mediators such as perilipin [67], a lipid droplet-associated 
protein, adipose triglyceride lipase (ATGL), a triglyceride lipase [68, 69], 
comparative gene identification-58 (CGI-58), a co-activator of ATGL [67] and 
hormone sensitive lipase (HSL) [70] in hepatic lipid accumulation. Furthermore, 
ATGL, which has highest affinity for triglyceride lipolysis in the adipocyte, plays 
a role in hepatic endoplasmic reticulum (ER) stress, a characteristic of NAFLD 
[71]. The stiffness in the distribution of hepatic fatty acids to form LPA is crucial 
due to its role in de novo lipogenesis. LPA is the substrate for the 
lysophosphatidic acid acyltransferase (LPAT) reaction catalysed by 
adiponutrin/PNPLA3 [72]. A polymorphism rs738409 C/G, encoding the 
PNPLA3 I148M variant has been consistently identified in NAFLD GWAS 
studies in various populations [4, 73-75]. The molecular function of PNPLA3 and 
the effect of the rs738409 polymorphism on it are only recently being understood 
[72, 76]. Li et al reported that overexpression of PNPLA3 I148M in the liver, but 
not adipocyte, results in hepatic steatosis in mice due to increased triglyceride 
synthesis and reduced triglyceride hydrolysis. The increase in triglyceride 
synthesis is potentially via the monoglyceride pathway as no accumulations in 
phosphatidic acid or DAG were observed. However, overexpression of wild-type 
PNPLA3 has no effects on hepatic fat indicating additional regulatory effects of 
the polymorphism apart from overexpression in triggering steatosis. The low 
tolerance of the branch-point determining the distribution of fatty acids to LPA 
formation may act as a mechanism to ensure limited availability of substrate for 
triglyceride synthesis and hence, a breach of this limited flux range may trigger 
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hepatic triglyceride accumulation, especially in the presence of the PNPLA3 
I148M polymorphism. 
Several branch points with medium or low values of  also display low flux 
range tolerance in several pathways (Table 2 and Table 3). Branch-points with 
moderate sensitivity include the lipid metabolic pathways involving LPA 
formation in the adipocyte, triglyceride hydrolysis in the liver, fatty acid transport 
from the serum to the liver and the formation of cholesterol esters. 
 
3.2.3 Regulators of branch-points with high  
Pathway branch-points with high values of  were further investigated to 
identify molecular regulators that are sensitive to alterations in flux distributions 
at these branches, by calculating their concentrations control coefficients with 
respect to various regulatory proteins in the SteatoNet,  (equation 23). Figure 7 
illustrates the regulatory factors with high sensitivity to alterations in flux 
distributions at the respective branch-points.  FXR, a regulator of bile acid 
synthesis and excretion, LXR, a sterol-sensor, and SREBP2, the key regulator of 
cholesterol synthesis, display global sensitivity to alterations in metabolic flux 
distribution at a majority of the high sensitivity pathway branches, indicating the 
broad role of these transcription factors that predominantly have a common 
function in cholesterol metabolism.  FXR is repressed by the transcription factor 
Yin Yang 1 resulting in hepatic steatosis in high-fat diet-induced obese mice [77] 
and has been identified as a target for NAFLD treatment [78]. Moreover, NAFLD 
patients display low levels of FXR expression along with increased expression of 
LXR and SREBP1c, which contributes to increased hepatic triglyceride synthesis 
[79]. Excess cholesterol accumulation in the liver triggers the activation of LXR 
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for cholesterol export and inhibits SREBP2-mediated de novo cholesterol 
synthesis by an auto-inhibitory mechanism [80, 81]. Thus, the global sensitivity of 
FXR, LXR and SREBP2, as observed in the SteatoNet, further emphasises on the 
role of cholesterol in maintaining lipid homeostasis in the liver. 
Interestingly, a majority of the transcription factors and metabolic regulators 
displayed sensitivity to alterations in the flux distribution in the glucose transport 
pathway (Figure 7) indicating the global effect of glucose on metabolic regulation. 
Furthermore, it can be observed that transcriptional factors that are not directly 
involved in regulating a particular pathway may still be sensitive to the 
distribution of fluxes into the pathway (Figure 7) e.g. the sensitivity of FXR and 
SREBP2 to branch-points in the early hepatic glucose metabolism pathway. This 
can be explained by the largely interconnected nature of metabolic networks, 
whereby products generated by one pathway are utilised as substrates by another 
pathway. Thus, the inter-dependency of pathways may simultaneously be 
controlled by a balance in the levels of various transcriptional factors, providing 
further evidence of the network-wide disturbances in NAFLD-related steatosis.  
 
4. CONCLUSIONS 
As rightly suggested by Lanpher et al [82], most complex diseases can be described 
as less severe cases of Mendelian inborn errors of metabolism (IEM) in which several 
pathways are subtly affected. The cumulative effect of genomic variations and 
environmental/dietary factors results in altered metabolic flux distributions and hence, 
a broad spectrum of disease phenotypes. Thus, utilising a holistic approach, in 
addition to traditional reductionist methods, to study disease-related networks, termed 
as systems pathobiology, will provide a clearer portrait of the systemic deregulations 
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in complex diseases [83]. It will also enable drug development strategies to be 
redirected towards systemic medicine and multi-targeting approaches to identify 
appropriate treatment regimen. In this article we provide evidence that NAFLD is not 
trivially the hepatic manifestation of the metabolic syndrome, as commonly described 
according to Oslerian theory [84] that focuses specifically on the dysfunctional organ 
in a disease, but instead arises as a result of network-wide perturbations at the 
organism-level. While experimental evidence has long before indicated the systemic 
nature of NAFLD pathogenesis involving the role of the adipose tissue [85, 86], 
skeletal muscles [87, 88], intestine [89] and the heart [90, 91], there has been a lack of 
directed efforts to study NAFLD as a systemic condition.  
The validated multi-tissue metabolic network, SteatoNet, presented here provides a 
cohesive illustration of the cascade of disruptions caused by altered flux distributions 
that may have been triggered in a separate tissue such as the adipose, ultimately 
resulting in hepatic steatosis. SteatoNet highlights the ability of models to sufficiently 
represent biological behaviour in steady-state analysis in the absence of kinetic 
parameters. Parameter estimation is a major hurdle in modelling biological networks 
as the extrapolation of kinetic parameters from isolated in vitro studies to multi-
pathway networks has several drawbacks and need careful interpretation due to the 
presence of inconsistencies in kinetic measurements and multiple isoforms of 
enzymes, which are tissue- or substrate- specific. Fitting models based on optimizing 
model behaviour, objective functions and experimental data leads to large 
inconsistencies in parameter values and hence, unless very accurately measured, 
kinetic parameters cannot be constrained to generate useful predictions [92]. The 
normalization of variable parameters in SteatoNet provides a semi-quantitative 
description of the model variables, thus curbing the need for specifically constraining 
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parameters using kinetic data that are at present poorly documented, display 
variability and are measured in vitro under sub-optimal conditions that are 
incompatible to molecular behaviour in vivo. Model validation and the identification 
of flux disturbances by sensitivity analysis that have been previously proven 
experimentally in NAFLD patients/models indicate that accurate model parameter 
estimation is not critical for models investigating systemic steady-state behaviour to 
identify candidates for complex diseases. In cases where the scope of the model 
requires the accurate dynamic investigation of specific variables, especially to identify 
fine time-dependent alterations in molecular dynamics, parameter estimation is 
indisputably a crucial step. As the scope of SteatoNet was aimed at providing an 
overview of systemic steady-state behaviour to identify pivotal focal-points of system 
instability that may be causal of NAFLD pathogenesis, the simplification of kinetic 
behaviour does not affect the performance of the model. While simplifying reaction-
specific information, we stress on the importance of expansiveness and structural 
accuracy in models of biological systems. In spite of the success of dynamic 
modelling efforts, a majority of the models generated for eukaryotic organisms 
portray a simplified picture of molecular interactions. While a simplification of intra-
pathway complexity is advantageous in terms of model analysis, it leads to a loss of 
information if inter-pathway and tissue-tissue interactions are over-simplified. Palsson 
et al proved the importance of the completeness in model structural complexity by 
comparing models with different complexity levels for interpreting results from 
model sensitivity analysis [93]. Since, the physiological state of organisms is a result 
of complex system-wide interactions, analysing individual pathways in isolation leads 
to loss of information and inaccurate interpretations. Such an approach is a 
fundamental primary step in systems pathobiology by analysing the broad scheme of 
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the ‘candidate’ disease network and then channelling efforts towards specific 
molecular interactions. 
An additional dominant feature of the SteatoNet is the portrayal of feedback 
regulatory mechanisms at the transcriptional and post-translational level. Robustness 
is an inherent property of biological systems resulting from complex feedback control 
mechanisms elicited by a multitude of regulatory factors [23]. In the presence of 
system perturbations, robustness enables systems operating at an equilibrium state to 
either obtain a different nominal steady state or restore the initial equilibrium. Despite 
the simplified linear depiction of feedback regulation in SteatoNet, the inclusion of 
regulatory mechanisms is of fundamental nature and beneficial in maintaining 
network robustness and concurring effectively with biological behaviour.   
Here, we have provided a comprehensive sensitivity analysis highlighting the effects 
of altered flux distributions in metabolic pathways on hepatic steatosis. The critical 
dependence of hepatic triglyceride concentration on inter-tissue transport reactions 
highlights the multi-tissue nature of NAFLD and thus, the disruption in the 
homeostatic balance in the distribution of numerous metabolites is at least in part 
causal of the disease state. Moreover, the analysis provides a hypothesis for the chain 
of events that trigger the disease whereby the accumulation of hepatic triglycerides is 
initially triggered due to a deregulation in stiff pathway branch-points with low 
tolerance to flux alterations. The function of these stiff focal points in the early steps 
of hepatic lipogenesis and in the adipose compartment in maintaining a balance in 
triglyceride synthesis, storage and hydrolysis may indicate their initial role in 
triggering hepatic steatosis. The “threshold effect” displayed by the stiff branch-points 
beyond which the altered metabolic fluxes result in disease initiation may be specific 
to individuals and potentially explain the variability in NAFLD pathogenesis, 
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especially in the case of the stiff LPAT reaction catalysed by adiponutrin, whose 
PNPLA3 I148M variant is commonly observed in diverse NAFLD populations. 
Instability in these low tolerance reactions may elicit functional changes in regulatory 
factors such as FXR and LXR, which in turn activate a cascade of alterations in 
numerous pathways that are sensitive to these factors, thus resulting in a pathological 
state. In addition to confirming hepatic triglyceride sensitivity to previously identified 
deregulations in NAFLD, the model has allowed the identification of candidate 
mechanisms such as cholesterol, glucose and ketone body transport and metabolism 
and regulatory functions of FXR, LXR and SREBP-2 that require experimental focus 
in the future. However, the question still remains on potential mechanisms that result 
in altered flux distributions. As stated by Magnuson et al, the regulation of metabolic 
flux is a complex phenomenon that cannot be pinpointed to a single mechanism, as 
metabolic pathways are intricately connected, involve multiple enzyme isoforms with 
different substrates that are regulated by numerous factors at the transcriptional and 
translational level [94]. Moreover, the inconsistency between the high prevalence of 
NAFLD and the small number of genetic variants identified in association with the 
disease indicates the critical role of environmental and dietary factors in initiating 
hepatic steatosis. Excessive dietary lipid or carbohydrate intake, and hence, 
overproduction of metabolic substrates may result in enzyme saturation, forcing a 
shift of metabolic flux into alternative pathways. In addition, dietary factors cause 
diverse changes in the metabolic status of an organism by triggering the activation or 
inhibition of regulatory factors such as hormones, cytokines and nuclear receptors 
[95, 96]. Individuals with genetic variations or inborn errors in metabolism affecting 
the activity or concentration of enzymes or regulatory factors may be predisposed to 
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hepatic steatosis as a result of inherent deregulations in flux distributions, with further 
adverse effects in the absence of suitable dietary measures.  
In spite of the significance and informative nature of the SteatoNet in identifying 
candidate mechanisms/mediators in NAFLD pathogenesis and generating hypotheses 
for experimental validation, we are aware of drawbacks such as the model’s lack of 
quantitative prediction capacity. The problem of parameter estimation in complex 
models is a major limiting factor for accurate reconstructions of biological pathways 
and thus, modelling single cell or multi-compartmental model systems often involves 
assumptions to simplify complex biological phenomena. Hence, models are by no 
means a complete picture of the system under study and results from model analysis 
need to be interpreted with caution. However, the semi-quantitative accuracy obtained 
from the dynamic non-linear system presented here indicates the strength in the 
structural properties of models rather than accurate parameter estimation, which 
requires extensive time-course experiments and measurements of a large number of 
variables. Additionally, the one-at-a-time method of local sensitivity analysis 
implemented in this article estimates sensitivity to only single parameters rather than 
the interaction between several parameters, which requires increased computational 
time due to the large number of simulations that need to be generated to test variations 
in numerous parameters simultaneously. Using variance-based methods that account 
for multi-parameter interactions is a topic of future interest, to determine if multiple 
flux alterations influence the degree of hepatic steatosis. Future work will involve the 
utilisation of the model to aid in experimental design and establish it as an integrative 
platform to analyze different data types. The non-specific nature of the model also 
enables its utility to investigate a wide-range of biological phenomena and other 
metabolic disorders. While the scope of this study was limited to identifying the flux 
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branch-points that potentially trigger hepatic steatosis, the first stage of NAFLD 
pathogenesis, it may be interesting to determine factors that affect the progression of 
steatosis into NASH and hepatocellular carcinoma by analyzing the sensitivity of 
inflammatory and oncogenic mediators to deregulated lipid homeostasis. The 
inclusion of interactions with other relevant compartments such as the gut and heart 
may also highlight additional mechanisms involved in NAFLD.  
In summary, SteatoNet provides a unique multi-tissue, dynamic, semi-quantitative 
platform for in silico ‘experimentation’, in order to investigate complex metabolic 
disorders such as NAFLD. The strength of SteatoNet lies in its structural accuracy, 
robustness, expansiveness and the inclusion of regulatory feedback mechanisms at 
various hierarchical levels controlling metabolic networks that allows systemic 
behavioural analysis in the absence of estimated kinetic parameters. The network 
characteristic of NAFLD pathogenesis triggered due to alterations in flux distributions 
at low-threshold focal points in the network, which cascades the perturbations to 
interacting pathways (cholesterol, glucose and ketone body transport) and regulatory 
factors directly influencing hepatic triglyceride concentration, a hypothesis suggested 
by SteatoNet analysis, requires experimental validation.  
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Table I. Pathway branch-points with high sensitivity and low flux range tolerance. FA- 
Fatty acids, Gly-3-P- Glycero-3-phosphate, LPA- Lysophosphatidic acid, TG- Triglycerides, 
LD- Lipid droplets, A- adipose compartment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATHWAY BRANCH FLUX RANGE SENSITIVITY 
FA (+ Gly-3-P) to LPA Upto 10% of total flux into 
fatty acids 
2.098 
TG storage in LDA 20-30% of total flux into 
adipocyte triglycerides 
1.224 
TGA to DAGA 50-60% of total flux into 
adipose triglycerides 
2.781 
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PATHWAY BRANCH FLUX RANGE SENSITIVITY 
G-6-P to G-1-P Upto 40% of total flux into 
glucose 
-0.6 to -0.2 
Cholesterol + SFA CoA 
to Cholesterol esters 
Upto 10% of total flux into 
saturated fatty acyl CoA 
-0.2 
FAA (+ Gly-3-P) to LPAA Upto 30% of total flux into 
fatty acyl CoAA 
-0.5 to -0.14 
FAB to MUFAL Upto 30% of total flux into 
serum fatty acids 
0.14 to 0.36 
TGL to DAGL Upto 40% of total flux into 
liver triglycerides 
0.3 
 
Table II. Pathway branch-points with medium sensitivity and low flux range tolerance. 
G-6-P- Glucose-6-phosphate, G-1-P- Glucose-1-phosphate, SFA- Saturated fatty acids, FA- 
Fatty acids, Gly-3-P- Glycero-3-phosphate, LPA- Lysophosphatidic acid, MUFA- 
Monounsaturated fatty acids, TG- Triglycerides, DAG- Diacylglycerol, A- adipose, B- 
blood/serum, L-liver. 
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PATHWAY BRANCH FLUX RANGE SENSITIVITY 
G-6-P to Ribulose-5-P Upto 30% of total flux into 
glucose 
-0.08 to -0.05 
Serine to Glycine Upto 30% of total flux into 
serine 
-0.00015 to 0.00056 
Serine+Homocysteine to 
Cystathionine 
Upto 30% of total flux into 
serine 
0.00235 to 0.00475 
Glutamate to Glutamic 
semialdehyde 
Upto 20% of total flux into 
glutamate 
0.0032 
DAG+Choline to 
Phosphatidylcholine 
Upto 40% of total flux in 
DAG 
0.015 to 0.031 
Cholesterol + USFA CoA 
to Cholesterol esters 
Upto10% of total flux into 
USFA CoA 
-0.02 
CholesterolA synthesis Upto 20% of total flux into 
acetyl CoA adipocyte 
0.00014 
Acetyl CoAT to Malonyl 
CoAT  
Upto 30% of total flux into 
acetyl CoA tissue 
-5.12E-06 to -7.89E-06 
CholesterolT synthesis Upto 20% of total flux into 
acetyl CoA tissue 
0.000102 
DHAP to Gly-3-P Upto 20% of total flux into 
DHAP 
-0.07 
DAG to MAG Upto 30% of total flux into 
DAG 
-0.1 to -0.04 
 
Table III. Pathway branch-points with low sensitivity and low flux range tolerance. G-6-
P- Glucose-6-phosphate, Ribulose-5-P- Ribulose-5-phosphate, DAG- Diacylglycerol, USFA- 
Unsaturated fatty acids, DHAP- Dihydroxyacetone phosphate, Gly-3-P- Glycero-3-
phosphate, MAG- Monoacylglycerol, T- peripheral tissues. 
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Figure 1. Dynamics of an enzymatic reaction according to the Michaelis-Menten kinetic 
formalism. S,E,C and P denote the concentrations of the substrate, enzyme, substrate-
enzyme complex and product respectively,  and  denote the rate constant of complex 
formation and product formation respectively,  and  denote the reverse reaction rate 
constant of complex dissociation into the enzyme and substrate and  product reversibility to 
complex respectively.  corresponds to the substrate influx into the reaction, corresponds 
to the product efflux of the reaction,  corresponds to the influx of enzyme into the 
reaction,  corresponds to the degradation of enzyme and f denotes the proportion of the 
total substrate influx into alternative pathways. 
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Figure 2. SteatoNet metabolic network. The multi-compartmental network was generated 
by systematically linking objects representing biological entities (e.g. metabolites, proteins, 
gene expression etc.) from the systems biology library, based on pathway evidence from 
KEGG, the Reactome and literature searches. The key metabolic pathways including glucose, 
fatty acid, cholesterol and amino acid metabolism and their regulation by hormonal, 
adipokine and transcriptional and post-translational regulatory factors are represented in the 
hepatic, adipose, macrophage, peripheral tissue and pancreatic compartments with inter-
tissue connectivity via the blood. The SteatoNet consists of 194 reactions involving 159 
metabolites, 224 enzymes and 31 non-enzymatic regulatory proteins. 
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Figure 3. Model validation of fasting conditions. Fasting conditions were simulated by 
reducing the influx of the glucose into the network by 10-fold. In accordance with biological 
observations, model simulations indicate a downregulation of serum insulin, serum glucose, 
glycogen stores, lipogenic enzymes (ACC1, FAS and SREBP1c) and increased levels of 
serum glucagon, PEPCK, serum fatty acids (FAB) and the β-oxidation enzyme, CPT-1 in 
response to the change in glucose influx into the network.  
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Figure 4. Model validation of SCD knockout conditions on a lipogenic and high-fat diet. 
The SCD knockout condition was simulated by increasing the rate of SCD enzyme 
degradation by 1000-fold, resulting in SCD enzyme levels approaching 0. The lipogenic diet 
was simulated by increasing the glucose network influx by 10-fold (until time 1x105) and the 
high fat diet was simulated by increasing the chylomicron and cholesterol network influx by 
5-fold and 4-fold (between time 1x105 and 2x105), respectively and decreasing the glucose 
influx by 2.5-fold. The absence of SCD resulted in a decrease in hepatic triglyceride 
accumulation and increase in the levels of CPT 1 and ketone bodies on both diets. The 
lipogenic diet triggered an upregulation of FAS and GPAT and their transcriptional regulator 
SREBP-1c, whereas these proteins were downregulated on the high fat diet. 
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Figure 5. Model validation of adiponectin overexpression under fasting conditions. 
Overexpression of adiponectin under fasting conditions was simulated by decreasing the rate 
of adiponectin degradation by 10-fold, resulting in increased levels of adiponectin and the 
glucose influx was reduced by 10-fold. In concordance with experimental observations, 
increased adiponectin concentration results in downregulation of serum fatty acids (FAB), 
hepatic triglycerides (TG), TNF-α, ceramides, SREBP1c, GPAT and SCD and increased 
expression of adipose CPT-1 (CPT-1A), with no changes in serum ketone bodies 
concentration. 
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Figure 6. High dynamic concentration control coefficients of branch-points SteatoNet. 
Range of concentration control coefficients of a) activation of saturated (SFA) and 
unsaturated (USFA) fatty acids in adipose, b) desaturation of SFA into USFA in adipose, c) 
breakdown of chylomicron (CM) into chylomicron remnants, d) reverse cholesterol transport, 
e) Low density lipoprotein (LDL) distribution to adipose and peripheral tissues, f) fructose-6-
phosphate synthesis from glucose-6-phosphate, g) glucose transport to adipose, h) hepatic 
release of glucose into blood, i) β-hydroxybutyrate (BHB) synthesis from 3-hydroxy 3-
methylglutaryl coenzyme A (HMG CoA), j) acetoacetate transport to blood, and k) uptake of 
ketone bodies (KB) by adipose,; with respect to hepatic triglyceride concentration. 
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Figure 7. Pathway branch-points and regulatory factors with high concentration control 
coefficients to hepatic triglyceride sensitivity. Concentration control coefficients ( ) of 
pathway branch-points were calculated with respect to hepatic triglyceride concentration and 
the concentration of various transcriptional and post-translational pathway regulators, by 
altering the initial flux distribution parameter ( ) of each branch-point in the network by 
intervals of 10% and determining the change in triglyceride or regulator concentration. The 
pathways in bold highlight high dynamic sensitivity branch-points while the others specify 
high-sensitivity+ low tolerance ‘stiff’ branch-points. Pathway regulators that are influenced 
by alterations in flux distribution are labelled at the corresponding branch-point to which they 
are sensitive. LXR- Liver X Receptor, SREBP-1c- Sterol Regulatory Element-Binding 
Protein-1c, TAG/TG- Triacylglycerol/ Triglycerides, ChREBP- Carbohydrate Response 
Element-Binding Protein, AMPK- Adenosine Monophosphate-regulated Protein Kinase, 
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VLDL- Very-Low Density Lipoprotein, LDL- Low density lipoprotein, SREBP-2- Sterol 
Regulatory Element-Binding Protein-2, TNFA- Tumour Necrosis Factor alpha, FA- Fatty 
Acids, G6P- Glucose-6-Phosphate, F6P- Fructose-6-Phosphate, USFA- Unsaturated Fatty 
Acids, G3P- Glycerol-3-Phosphate, LPA- Lysophosphatidic Acid, HMG CoA- 3-Hydroxy 3-
Methylglutaryl Coenzyme A, BHB- Beta-Hydroxybutyrate, HDL- High-density Lipoprotein, 
CM- Chylomicron, SFA- Saturated Fatty Acids, MAG- Monoacylglycerol, DAG- 
Diacylglycerol, LD- Lipid Droplets, DHAP- Dihydroxyacetone Phosphate, F16BP- Fructose-
1-6 Biaphosphate, Adipo R1/R2- Adiponectin Receptor 1/2, PPARA- Peroxisome 
Proliferator-Activated Receptor alpha, FXR- Farnesoid X Receptor, PGC1A- Peroxisome 
Proliferator-Activated Receptor gamma Coactivator 1 alpha, TLR4- Toll-like Receptors 4, 
PXR- Pregnane X Receptor. 
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SUPPLEMENTARY INFORMATION 
 
Supplementary Figure 1. Complete set of equations describing metabolic flux 
distribution at pathway branch points in the SteatoNet liver compartment. 
 
Pathway branch   
Blood_glucose -> Adipose_glucose 0.4 
0.2 
Hepatic_glucose -> Blood_glucose  
Glucose_source 
Blood_glucose -> Tissue_glucose 0.4 
0.2 
Hepatic_glucose -> Blood_glucose  
Glucose_source 
Hepatic_glucose -> Blood_glucose 0.1 
0.8 
Blood_glucose -> Hepatic_glucose 
Glucose-6-P -> Hepatic_glucose 
Glucose-6P -> Glucose-1P 0.2 Hepatic_glucose -> Glucose-6P 
Glucose-6P -> Fructose-6P 0.5 Hepatic_glucose -> Glucose-6P 
Glucose-6P -> Ribulose-5P 0.05 Hepatic_glucose -> Glucose-6P 
Glycogen -> Glucose-1P 0.5 UDP-Glucose -> Glycogen 
Fructose-6P -> Fructose-2,6BP 0.1 (Glucose-6P -> Fructose6P) + (Fructose-1,6BP -> Fructose-
6P) + (Fructose-2,6BP -> Fructose-6P) + (Xylulose-5P + 
Erythrose-4P -> Glyceraldehyde-3P + Fructose-6P) + 
(Sedoheptulose-7P + Glyceraldehyde-3P -> Fructose-6P + 
Erythrose-4P) 
Fructose-1,6BP -> DHAP 0.2 Fructose-6P -> Fructose-1,6BP 
Fructose-1,6BP -> Glyceraldehyde-
3P 
0.2 Fructose-6P -> Fructose-1,6BP 
DHAP -> Glycerol-3P 0.1 Fructose-1,6BP -> DHAP 
Lactate -> Pyruvate 0.3 
0.05 
Lactate_source 
Pyruvate -> Lactate 
Pyruvate -> Oxaloacetate 0.1 (PEP -> Pyruvate) + (Lactate -> Pyruvate) + (Serine -> 
Pyruvate + Ammonia) + (Cysteine -> Pyruvate + Ammonia) 
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+ (Malate -> Pyruvate) 
Pyruvate -> mito_AcetylCoA 0.1 (PEP -> Pyruvate) + (Lactate -> Pyruvate) + (Serine -> 
Pyruvate + Ammonia) + (Cysteine -> Pyruvate + Ammonia) 
+ (Malate -> Pyruvate) 
Oxaloacetate -> PEP 0.3 (Pyruvate -> Oxaloacetate) + (Citrate -> AcetylCoA + 
Oxaloacetate) + (Malate -> Oxaloacetate) 
AcetylCoA -> cyto_HMGCoA 0.1 (Citrate -> AcetylCoA + Oxaloacetate) + (MalonylCoA -> 
cyto_AcetylCoA) 
MalonylCoA -> cyto_AcetylCoA 0.1 cyto_AcetylCoA -> MalonylCoA 
Glycerate-3P -> Phospho-3-
hydroxypyruvate 
0.7 Glyceraldehyde -> -> -> Glycerate2P 
Serine -> Glycine 0.1 (Phospho-3-serine -> Serine) + Serine_source 
Serine -> Pyruvate + Ammonia 0.5 (Phospho-3-serine -> Serine) + Serine_source 
Cysteine -> Pyruvate + Ammonia 0.3 (Cystathionine -> Cysteine) + Cysteine_source 
Methionine -> Homocysteine 0.4 (Homocysteine -> Methionine) + Methionine_source 
Homocysteine + Serine -> 
Cystathionine 
0.1 (Phospho-3-serine -> Serine) + Serine_source 
Phenylalanine -> Tyrosine 0.1 Phenylalanine_source 
Tyrosine -> Acetoacetate + 
Fumarate 
0.1 (Phenylalanine -> Tyrosine) + Tyrosine_source 
Oxoglutarate + Ammonia -> 
Glutamate 
0.3 
1.0 
 
1.0 
1.0 
 
1.0 
Oxalosuccinate -> Oxoglutarate 
Oxaloacetate + Glutamate -> Aspartate + Oxoglutarate 
Pyruvate + Glutamate -> Alanine + Oxoglutarate 
Glutamic_Semialdehyde + Glutamine -> Arginine+ 
Oxoglutarate 
Glutamic_Semialdehyde + Glutamate -> Ornithine + 
Oxoglutarate 
Glutamate -> -> 
Glutamic_Semialdehyde 
0.05 (Oxoglutarate + Ammonia -> Glutamate) + 
Glutamate_source + (Aspartate + Glutamine -> Asparagine 
+ Glutamate) + (Glutamine -> Glutamate + Ammonia) + 
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(Histidine -> Glutamate) 
Glutamate + Ammonia -> Glutamine 0.5 (Oxoglutarate + Ammonia -> Glutamate) + 
Glutamate_source + (Aspartate + Glutamine -> Asparagine 
+ Glutamate) + (Glutamine -> Glutamate + Ammonia) + 
(Histidine -> Glutamate) 
Glutamine -> Glutamate + Ammonia 0.7 Glutamine_source + (Glutamate + Ammonia -> Glutamine) 
Pyruvate + Glutamate -> Alanine + 
Oxoglutarate 
0.3 (PEP -> Pyruvate) + (Lactate -> Pyruvate) + (Serine -> 
Pyruvate + Ammonia) + (Cysteine -> Pyruvate + Ammonia) 
+ (Malate -> Pyruvate) 
Aspartate + Glutamine -> 
Asparagine + Glutamate 
0.1 (Oxaloacetate + Glutamate -> Aspartate + Oxoglutarate) + 
Aspartate_source 
Glutamic_Semialdehyde + 
Glutamine -> Arginine + 
Oxoglutarate 
0.1 Glutamate ->-> Glutamic_Semialdehyde 
Isoleucine -> PropionylCoA 0.1 Isoleucine_source 
Valine_to_PropionylCoA 0.1 Valine_source 
Alpha_Ketobutyrate -> 
PropionylCoA 
0.1 Cystathionine -> Cysteine 
PropionylCoA -> 
MethylmalonylCoA 
0.1 (Isoleucine -> PropionylCoA) + (Valine_to_PropionylCoA) 
+ (Alpha_Ketobutyrate -> PropionylCoA) 
Histidine -> Glutamate 0.1 Histidine_source 
Leucine -> HMGCoA 0.1 Leucine_source 
Tryptophan -> Alanine + 
Hydroxy_3_Anthranilate 
0.1 Tryptophan_source 
Oxaloacetate + Glutamate -> 
Aspartate + Oxoglutarate 
0.4 (Pyruvate -> Oxaloacetate) + (Citrate -> AcetylCoA + 
Oxaloacetate) + (Malate -> Oxaloacetate) 
Arginine -> Urea + Ornithine 0.9 Arginine_source + (Glutamic_Semialdehyde + Glutamine -
> Arginine + Oxoglutarate) 
Glutamic_Semialdehyde + 0.1 Glutamate ->-> Glutamic_Semialdehyde 
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Glutamate -> Ornithine + 
Oxoglutarate 
Carbamoyl_phosphate + Ornithine -
> Citrulline 
0.2 (Glutamic_Semialdehyde + Glutamate -> Ornithine + 
Oxoglutarate) + (Arginine -> Urea + Ornithine) 
Citrate -> CisAconitate 0.6 mito_AcetylCoA + Oxaloacetate -> Citrate 
Malate -> Oxaloacetate 0.8 
0.1 
Fumarate -> Malate 
Oxaloacetate -> Malate 
Keto-3-AcylCoA -> AcylCoA 0.2 Trans2BEnoylCoA -> Keto-3-AcylCoA 
SuccinylCoA + Acetoacetate -> 
Succinate + AcetoacetylCoA 
0.1 SSuccinylDihydrolipamideE1 -> SuccinylCoA 
mito_AcetylCoA + Oxaloacetate -> 
Citrate 
0.2 (Pyruvate -> Oxaloacetate) + (Citrate -> AcetylCoA + 
Oxaloacetate) + (Malate -> Oxaloacetate) 
Acetoacetate -> blood_Acetoacetate 0.4 
0.2 
HMGCoA -> Acetoacetate 
Tyrosine -> Acetoacetate + Fumarate 
Acetoacetate -> BHydroxybutyrate 0.5 
0.2 
HMGCoA -> Acetoacetate 
Tyrosine -> Acetoacetate + Fumarate 
blood_BHydroxybutyrate -> adipo_ 
BHydroxybutyrate 
0.5 BHydroxybutyrate -> blood_ BHydroxybutyrate 
blood_Acetoacetate -> adipo_ 
Acetoacetate 
0.5 Acetoacetate -> blood_ Acetoacetate 
Palmitate -> Keto-3-Sphingosine 0.01 (MalonylCoA + AcetylCoA -> Palmitate) + 
(blood_Palmitate -> Palmitate) 
PalmitoylCoA -> PalmitoleateCoA 0.9 Palmitate -> PalmitoylCoA 
PalmitoleoylCoA + Glycerol3P -> 
LPA 
0.05 (Palmitoleate -> PalmitoleoylCoA) + (PalmitoylCoA -> 
PalmitoleoylCoA) 
DAG + Choline -> PC 0.2 (TG -> DAG) + (PA -> DAG) + (MAG -> DAG) 
DAG -> MAG 0.1 (TG -> DAG) + (PA -> DAG) + (MAG -> DAG) 
PalmitoleateCoA  + DAG -> TG 0.5 (TG -> DAG) + (PA -> DAG) + (MAG -> DAG) 
TG_to_DAG 0.3 (PalmitoleateCoA  + DAG -> TG) + (blood_TG -> TG) + 
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(TG_lipid_droplet -> TG) 
TG -> VLDL 0.7 (Cholesterol + PalmitoleoylCoA -> Cholesteryl_esters) + 
(Cholesterol + PalmitoylCoA -> Cholesteryl_esters) 
TG -> TG_lipid_droplet 0.3 (PalmitoleoylCoA  + DAG -> TG) + (blood_TG -> TG) + 
(TG_lipid_droplet -> TG) 
MAG -> Glycerol 0.8 DAG -> MAG 
PC -> PA + Choline 0.2 DAG + Choline -> PC 
Cholesterol + PalmitoylCoA -> 
Cholesteryl_esters 
0.05 Palmitate -> PalmitoylCoA 
Cholesterol + PalmitoleoylCoA -> 
Cholesteryl_esters 
0.1 (Palmitoleate -> PalmitoleoylCoA) + (PalmitoylCoA -> 
PalmitoleoylCoA) 
Cholesterol_utilization 0.7 Cholesterol_source + (LDL_cholesterol -> Cholesterol) + 
(A_2_HDL -> Cholesterol) + (HMGCoA -> Cholesterol) 
blood_Cholesterol -> 
macrophage_Cholesterol 
0.3 (VLDL -> blood_fatty_acids) + (HDL -> VLDL + LDL) 
blood_Cholesterol -> 
adipo_Cholesterol 
0.3 (VLDL -> blood_fatty_acids) + (HDL -> VLDL + LDL) 
blood_Cholesterol -> 
tissue_Cholesterol 
0.3 (VLDL -> blood_fatty_acids) + (HDL -> VLDL + LDL) 
A_2_HDL -> Cholesterol 0.2 (A_4_HDL -> A_2_HDL + A_3_HDL) + (A_1_HDL -> 
A_2_HDL + VLDL) 
blood_Fatty_acids -> Palmitoleate 0.1 (adipo_Fatty_acids -> blood_Fatty_acids) + (VLDL -> 
blood_fatty_acids) + (Chylomicron_blood -> 
blood_Fatty_acids) 
Chylomicron -> 
Chylomicron_remnants 
0.5 Chylomicron_source 
 
 
 
